Citi analyst Yigal Nochomovitz downgraded Arvinas to Neutral from Buy with a price target of $55, up from $36. The analyst sees a balanced risk/reward following the stock’s recent rally. Arvinas has risen over 200% in the past three months, fueled in part by the vepdegestrant plus palbociclib Phase 1b efficacy update, the analyst tells investors in a research note. Citi cites valuation for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Goldman Sachs Predicts at Least 45% Rally for These 2 ‘Strong Buy’ Stocks — Here’s Why They Have Solid Upside
- Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
- Arvinas, Pfizer: FDA grants Fast Track designation for ARV-471
- 3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts
- Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference